Targeting cell death in dementia

Alzheimer Disease and Associated Disorders

Volumn 20, Issue SUPPL. 1, 2006, Pages

  Francis, Paul ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Cell death; Dementia; Neurodegeneration

Indexed keywords

AMYLOID BETA PROTEIN;

ALZHEIMER DISEASE; BRAIN HEMORRHAGE; BRAIN HYPOXIA; BRAIN ISCHEMIA; BRAIN PERFUSION; CHOLINERGIC NERVE; CONFERENCE PAPER; GLUCOSE OXIDATION; HUMAN; MULTIINFARCT DEMENTIA; NERVE DEGENERATION; NEUROCHEMISTRY; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; PRIORITY JOURNAL;

ALZHEIMER DISEASE; ATROPHY; BRAIN; CELL DEATH; CHOLINESTERASE INHIBITORS; DEMENTIA, VASCULAR; HUMANS; NECROSIS; NERVE DEGENERATION; NEURONS; TREATMENT OUTCOME;

EID: 33748118747     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.wad.0000213803.82058.46     Document Type: Conference Paper

References (42)

1. Bamberger ME, Landreth GE. Inflammation, apoptosis, and Alzheimer's disease. Neuroscientist. 2002;8:276-283.
2. Niwa M, Hara A, Iwai T, et al. Caspase activation as an apoptotic evidence in the gerbil hippocampal CA1 pyramidal cells following transient forebrain ischemia. Neurosci Lett. 2001;300:103-106.
3. Braak H, Braak E. Morphological criteria for the recognition of Alzheimer's disease and the distribution pattern of cortical changes related to this disorder. Neurobiol Aging. 1994;15:355-356.
4. Thal DR, Rub U, Orantes M, et al. Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology. 2002;58:1791-1800.
5. Francis PT, Sims NR, Procter AW, et al. Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease: investigative and therapeutic perspectives. J Neurochem. 1993;60:1589-1604.
6. Mergenthaler P, Dirnagl U, Meisel A. Pathophysiology of stroke: lessons from animal models. Metab Brain Dis. 2004;19:151-167.
7. Mattson MP, Pedersen WA, Duan W, et al. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann N Y Acad Sci. 1999;893:154-175.
8. Braak H, Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol Scand Suppl. 1996;165:3-12.
9. Mattson MP, Culmsee C, Yu ZF. Apoptotic and antiapoptotic mechanisms in stroke. Cell Tissue Res. 2000;301:173-187.
10. de la Torre JC. Vascular basis of Alzheimer's pathogenesis. Ann N Y Acad Sci. 2002;977:196-215.
11. Kalaria RN, Kenny RA, Ballard CG, et al. Towards defining the neuropathological substrates of vascular dementia. J Neurol Sci. 2004;226:75-80.
12. Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. JAMA. 1997;277:813-817.
13. Shimohama S. Apoptosis in Alzheimer's disease - an update. Apoptosis. 2000;5:9-16.
14. Jellinger KA, Stadelmann C. Problems of cell death in neurodegeneration and Alzheimer's disease. J Alzheimers Dis. 2001;3:31-40.
15. Kitamura Y, Shimohama S, Kamoshima W, et al. Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad, ICH-1 and CPP32, in Alzheimer's disease. Brain Res. 1998;780:260-269.
16. Yao M, Nguyen TV, Pike CJ. Beta-amyloid-induced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci. 2005;25:1149-1158.
17. Stadelmann C, Deckwerth TL, Srinivasan A, et al. Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol. 1999;155:1459-1466.
18. Gastard MC, Troncoso JC, Koliatsos VE. Caspase activation in the limbic cortex of subjects with early Alzheimer's disease. Ann Neurol. 2003;54:393-398.
19. Armstrong DM, Ikonomovic MD. AMPA-selective glutamate receptor subtype immunoreactivity in the hippocampal dentate gyrus of patients with Alzheimer disease. Evidence for hippocampal plasticity. Mol Chem Neuropathol. 1996;28:59-64.
20. Auld DS, Kar S, Quirion R. Beta-amyloid peptides as direct cholinergic neuromodulators: a missing link? Trends Neurosci. 1998;21:43-49.
21. Walsh DM, Klyubin I, Fadeeva JV, et al. Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature. 2002;416:535-539.
22. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 2000;283:1571-1577.
23. Dineley KT, Westerman M, Bui D, et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: in vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci. 2001;21:4125-4133.
24. Auld DS, Kornecook TJ, Bastianetto S, et al. Alzheimer's disease and the basal forebrain cholinergic system: relations to beta-amyloid peptides, cognition, and treatment strategies. Prog Neurobiol. 2002;68:209-245.
25. Francis PT. Glutamatergic systems in Alzheimer's disease. Int J Geriatr Psychiatry. 2003;18:S15-S21.
26. Mann DM, Neary D, Yates PO, et al. Neurofibrillary pathology and protein synthetic capability in nerve cells in Alzheimer's disease. Neuropathol Appl Neurobiol. 1981;7:37-47.
27. Gomez-Isla T, Hollister R, West H, et al. Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. Ann Neurol. 1997;41:17-24.
28. Neary D, Snowden JS, Mann DM, et al. Alzheimer's disease: a correlative study. J Neurol Neurosurg Psychiatry. 1986;49:229-237.
29. Dodd PR. Excited to death: different ways to lose your neurones. Biogerontology. 2002;3:51-56.
30. Thomson AM, Bannister AP. Interlaminar connections in the neocortex. Cereb Cortex. 2003;13:5-14.
31. Francis PT, Carl R, Pearson A, et al. The dementia of Alzheimer's disease: an update. J Neurol Neurosurg Psychiatry. 1987;50:242-243.
32. Harkany T, Mulder J, Horvath KM, et al. Oral post-lesion administration of 5-HT(1A) receptor agonist repinotan hydrochloride (BAYX3702) attenuates NMDA-induced delayed neuronal death in rat magnocellular nucleus basalis. Neuroscience. 2001;108:629-642.
33. Ikonomovic MD, Nocera R, Mizukami K, et al. Age-related loss of the AMPA receptor subunits GluR2/3 in the human nucleus basalis of Meynert. Exp Neurol. 2000;166:363-375.
34. Crossthwaite AJ, Valli H, Williams RJ. Inhibiting Src family tyrosine kinase activity blocks glutamate signalling to ERK1/2 and Akt/PKB but not JNK in cultured striatal neurones. J Neurochem. 2004;88:1127-1139.
35. Lee B, Butcher GQ, Hoyt KR, et al. Activity-dependent neuroprotection and cAMP response element-binding protein (CREB): kinase coupling, stimulus intensity, and temporal regulation of CREB phosphorylation at serine 133. J Neurosci. 2005;25:1137-1148.
36. Hardingham GE, Fukunaga Y, Bading H. Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat Neurosci. 2002;5:405-414.
37. Crossthwaite AJ, Hasan S, Williams RJ. Hydrogen peroxide-mediated phosphorylation of ERK1/2, Akt/PKB and JNK in cortical neurones: dependence on Ca(2+) and PI3-kinase. J Neurochem. 2002;80:24-35.
38. Kontush A. Amyloid-beta: an antioxidant that becomes a pro-oxidant and critically contributes to Alzheimer's disease. Free Radic Biol Med. 2001;31:1120-1131.
39. Takada Y, Yonezawa A, Kume T, et al. Nicotinic acetylcholine receptor-mediated neuroprotection by donepezil against glutamate neurotoxicity in rat cortical neurons. J Pharmacol Exp Ther. 2003;306:772-777.
40. Akasofu S, Kosasa T, Kimura M, et al. Protective effect of donepezil in a primary culture of rat cortical neurons exposed to oxygenglucose deprivation. Eur J Pharmacol. 2003;472:57-63.
41. Francis PT, Nordberg A, Arnold SE. A preclinical view of cholinesterase inhibitors in neuroprotection: do they provide more than symptomatic benefits in Alzheimer's disease? Trends Pharmacol Sci. 2004;26:104-111.
42. Michaelis ML. Drugs targeting Alzheimer's disease: some things old and some things new. J Pharmacol Exp Ther. 2003;304:897-904.